A frontline fighter in the war against microbes.
The bugs that make us sick are increasingly resistant to the drugs we’ve used (and misused) to fight them. By one estimate, antimicrobial resistance (AMR) will cause the deaths of 10 million people annually by 2050. BD’s products, including its test to rapidly detect drug-resistant tuberculosis and its infection-prevention equipment, are tools to combat AMR. BD also trains health workers to quickly and precisely diagnose and treat infection. In Uganda, with BD’s help, turnaround time for a TB test has fallen from three weeks to three days, reducing chances that a patient will go untreated or be given the wrong drug.
Company Information
| Country | U.S. |
| Headquarters | Franklin Lakes, N.J. |
| Impact Segment | Public Health/Nutrition |
| Sector | Healthcare |
| Industry | Medical Products and Equipment |
| CEO | Vincent Forlenza |
| Website | www.bd.com |
| Company Type | Public |
| Ticker | BDX |
| Prior Year Rank | - |
| Revenues ($M) (Last Fiscal Year) | $15,983 |
| Profits ($M) (Last Fiscal Year) | $311 |
| Market Value ($M) as of 8/12/19 | $67,262 |
| Employees | 76,032 |